Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Maturitas
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047–1059.
- Menopausal estrogen and estrogen–progestin replacement therapy and breast cancer risk.J Am Med Assoc. 2000; 283: 485-491
WHI. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women’s health initiative randomized controlled trial. J Am Med Assoc 2002;288:321–33.
WHI. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women’s health initiative randomized controlled trial. J Am Med Assoc 2004;291:1701–12.
- Breast-cancer risk following long-term oestrogen- and oestrogen–progestin-replacement therapy.Int J Cancer. 1999; 81: 339-344
Million women study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419–27.
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer form 54 epidemiological studies. Lancet 1996;347:1713–27.
- Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer.J Reprod Med. 1996; 41: 419-425
- Progestogen use and risk of breast cancer in a cohort study of premenopausal women with benign breast disease.Br J Cancer. 1994; 70: 270-277
- A correlative morphologic study of human breast and endometrium in the menstrual cycle.Am J Surg Pathol. 1986; 10: 382-393
- Proliferative and secretory activity in human breast during natural and artificial menstrual cycles.Am J Pathol. 1988; 130: 193-204
- Influence of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo.Fertil Steril. 1995; 63: 785-791
Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998;69:963, 969.
- Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postemenopausal breast.J Clin Endocrinol Metab. 1999; 84: 4559-4565
- Epithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement therapy.Br J Cancer. 1998; 78: 945-949
- Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density.Am J Obstet Gynecol. 2002; 186: 717-722
- Progestin effect on cell proliferation an 17 b-hydroxysteroid dehydrogenase activity in normal human breast cells in culture.J. Clin. Endocrinol. Metab. 1986; 63: 1174-1180
- Tibolone effects in breast cells in vitro studies.Fertil. Steril. 2002; 78: 351-359
- The effect of estrogen, progesterone, thyroxine, and human placental lactogen on DNA synthesis of human breast ductal epithelium maintained in athymic nude mice.Cancer. 1984; 54: 1920-1927
- Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor, epidermal growth factor, c-fos, and c-myc genes.Mol Cell Biol. 1991; 11: 5032-5043
- Antiestrogenic effect of R5020, a synthetic progestin in human breast cancer cells in culture.J. Clin. Endocrinol. Metab. 1983; 56: 1124-1130
- Mechanisms of cyclin-dependent kinase inactivation by progestins.Mol Cell Biol. 1998; 18: 1812-1825
- Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependant kinase inhibitors, p21 and p27kip1.Mol Endocrinol. 1997; 11: 1593-1607
- Convergence of progesterone with growth factor and cytokine signaling in breast cancer.J. Biol. Chem. 1998; 273: 31317-31326
- Morphology of hormone induced structural changes in the female breast.Curr. Top. 1970; 53: 1-89
- Chemo-prevention of N-nitro-N-methylurea-induced mammary cancers by pretreatment with 17 β-estradiol and progesterone.J. Natl. Cancer Inst. 1985; 74: 927-930
- In vitro studies of tibolone in breast cells.Fertil. Steril. 2002; 78: 351-359
- Proapoptotic effects of antiestrogens, progestines and androgen in breast cancer cells.J. Steroid Biochem. Mol. Bio. 1999; 69: 463-471
- Hormonal regulation of apoptosis in breast cells. Hormonal regulation of apoptosis in breast cells and tissues.Steroids. 2000; 65: 593-598
- Antiestrogens are pro-apoptotic in normal human breast epithelial cells.Int. J. Cancer. 2003; 105: 607-612
- Bcl-2 heterodimerizes in vivo with a conserved homologue bax that accelerates programmed cell death.Cell. 1993; 74: 609-619
- Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -7, -8, and -10 in a caspase-9 dependent manner.J. Cell Biol. 1999; 144: 281-292
- Antagonism between estradiol & progestin on bcl-2 expression in breast cancer cells.Int. J. Cancer. 1996; 68: 120-125
- Estrogen promotes chemotherapeutic drug resistance by a mechanism involving bcl-2 proto-oncogene expression in human breast cancer cells.Cancer Res. 1995; 55: 3902-3907
- Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis.Mol Endocrinol. 2002; 16: 70-84
- Progestin and G protein-coupled receptor 30 inhibit. Mitogen-activated protein kinase activity in MCF-7 breast cancer cells.Endocrinology. 2002; 143: 4620-4626
- G protein-coupled receptor 30 is critical for a progestin-induced growth inhibition in MCF-7 breast cancer cells.Endocrinology. 2002; 143: 3376-3384
- Endocrine-responsive breast cancer and strategies for combatting resistance.Nat Rev/Cancer. 2002; 2: 101-115
- Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis.Breast Cancer Res. Treat. 2002; 72: 163-172
- Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism.Mutation Res. 2000; 462: 323-333